摘要
通过诱发 CHL 细胞染色体畸变的体外试验和小鼠骨髓细胞染色体的体内试验这两条途径来检测该药的致突变性,结果显示:在体内试验中,氟苯咪唑(640—1280mg/kg)与阴性对照组(N.S)相比,有非常显著的差异(p<0.01);在体外试验中,氟苯咪唑(0.39—1.56μg/ml)培养24h 和48h 对 CHL 细胞所诱发的染色体变化率显阳性。
Flubendazole is an anthelmintic.The test examined mutagenecity of this drugs
according to Provisions For New Drug Approval of the Country.The mutagenecity tests were
performed with Chinese hamster lung cell test and micronucleus test.
The mice were used in the micronucleus test.The animals were divided in groups incl-
uding test drug group,cyclophosphamide(350 mg/kg)group(positive control),uad the N.S
group(negative control).The results showed that the mutagenecity of flabendazole(640-1280
mg/kg)is significant(p<0.01)as compared with the negative control.
The Chinese hamster lung cell test were divided in groups including test drugs group,
vineristini sulfas(8 μg/ml)group(positive control).The results also showed that flabendaz-
ole(0.39—1.56μg/ml)may induced gene mutation.
关键词
氟苯咪唑
药物
致突变
微核试验
flubendazole
mutagenicity
CHL test
micromucleus test
